Using nanoparticles to deliver cancer drugs offers a way to hit tumors with large doses of drugs while avoiding the harmful side effects that often come with chemotherapy. However, so far, only a handful of nanoparticle-based cancer drugs have been FDA-approved.
A new study from MIT and Broad Institute of MIT and Harvard researchers may help to overcome some of the obstacles to the development of nanoparticle-based drugs. The team’s analysis of the interactions between 35 different types of nanoparticles and nearly 500 types of cancer cells revealed thousands of biological traits that influence whether those cells take up different types of nanoparticles.
Nanosynth Group plc (LON:NNN) nano-technology business that originated in Nottingham from a partnership with Nottingham Trent University. Their core mission is to develop unique ways to produce and apply nano particles.